Randomized trial evaluates intratracheal corticosteroids' impact on BPD and survival in extremely preterm infants, suggesting a safer alternative to systemic treatments.
( JAMA . 2024;332(22):1889–1899. DOI: 10.1001/jama.2024.17380) Bronchopulmonary dysplasia (BPD) is a frequent and serious condition that affects extremely preterm infants, particularly those born before 28 weeks of gestation. While systemic corticosteroids are known to be effective in minimizing BPD, they carry a risk of adverse side effects. Intratracheal corticosteroids, which are administered directly into the lungs with surfactant, could offer a safer and potentially effective alternative. This study aimed to evaluate the effectiveness of early administration of intratracheal corticosteroids in preventing BPD and improving survival in extremely preterm infants.
No takes yet. Share an insight, caveat, or question.
Manley et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: